Richard Geoffrey Vile, PhD

  • 12524 Citations
  • 64 Scopus h-Index
1980 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Richard Geoffrey Vile is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 11 Similar Profiles
Neoplasms Medicine & Life Sciences
Oncolytic Viruses Medicine & Life Sciences
Genetic Therapy Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Melanoma Medicine & Life Sciences
Viruses Medicine & Life Sciences
Vesicular Stomatitis Medicine & Life Sciences
Oncolytic Virotherapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1980 2019

Oncolytic Viruses
Neoplasms
Therapeutics
Paclitaxel
Oncolytic Virotherapy
Oncolytic Virotherapy
Viruses
Neoplasms
Oncolytic Viruses
Vesicular Stomatitis
Melanocytes
Autoimmunity
Immunity
Melanoma
Neoplasms
Oncolytic Viruses
T-Lymphocytes
Genetic Therapy
Neoplasms
Viruses

Research Output 1989 2019

Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity

Schuelke, M. R., Wongthida, P., Thompson, J., Kottke, T., Driscoll, C. B., Huff, A. L., Shim, K. G., Coffey, M., Pulido, J. S., Evgin, L. & Vile, R. G., Jul 17 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 188.

Research output: Contribution to journalArticle

Open Access
Brain Stem Neoplasms
Immunotherapy
Brain Stem
Neoplasms
Pediatrics
1 Citation (Scopus)

Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition

Jennings, V. A., Scott, G. B., Rose, A. M. S., Scott, K. J., Migneco, G., Keller, B., Reilly, K., Donnelly, O., Peach, H., Dewar, D., Harrington, K. J., Pandha, H., Samson, A., Vile, R. G., Melcher, A. A. & Errington-Mais, F., Jan 1 2019, In : Molecular Therapy.

Research output: Contribution to journalArticle

Open Access
Oncolytic Viruses
Histone Deacetylases
Granulocyte-Macrophage Colony-Stimulating Factor
Simplexvirus
Natural Killer Cells

Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

Evgin, L., Huff, A. L., Kottke, T., Thompson, J., Molan, A. M., Driscoll, C. B., Schuelke, M., Shim, K. G., Wongthida, P., Ilett, E. J., Smith, K. K., Harris, R. S., Coffey, M., Pulido, J. S., Pandha, H., Selby, P. J., Harrington, K. J., Melcher, A. & Vile, R. G., May 1 2019, In : Cancer Immunology Research. 7, 5, p. 828-840 13 p.

Research output: Contribution to journalArticle

Cell- and Tissue-Based Therapy
T-Lymphocytes
Phenotype
Neoplasms
Genetic Therapy
4 Citations (Scopus)

Ad5NULL-A20: A tropism-modified, avb6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies

Uusi-Kerttula, H., Davies, J. A., Thompson, J. M., Wongthida, P., Evgin, L., Shim, K. G., Bradshaw, A., Baker, A. T., Rizkallah, P. J., Jones, R., Hanna, L., Hudson, E., Vile, R. G., Chester, J. D. & Parker, A. L., Sep 1 2018, In : Clinical Cancer Research. 24, 17, p. 4215-4224 10 p.

Research output: Contribution to journalArticle

Tropism
Adenoviridae
Integrins
Neoplasms
Transgenes
5 Citations (Scopus)

Antibody-neutralized reovirus is effective in oncolytic virotherapy

Berkeley, R. A., Steele, L. P., Mulder, A. A., Van Den Wollenberg, D. J. M., Kottke, T. J., Thompson, J., Coffey, M., Hoeben, R. C., Vile, R. G., Melcher, A. & Ilett, E. J., Oct 1 2018, In : Cancer immunology research. 6, 10, p. 1161-1173 13 p.

Research output: Contribution to journalArticle

Oncolytic Virotherapy
Oncolytic Viruses
Antibodies
Neutralizing Antibodies
Antiviral Agents